Replies to post #126647 on Biotech Values

[ghmm]

EXEL:

I don't follow but Martin's comments defintly have flare for dramatic. Here is Adam Feuerstein's tweet

$EXEL getting hit by story alleging more dose reductions in cabozantinib prostate cancer study due to tolerability issues.